Carnick & Kubik Group LLC Invests $1.38 Million in Merck & Co., Inc. (NYSE:MRK)

Carnick & Kubik Group LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 21,540 shares of the company’s stock, valued at approximately $1,379,000.

A number of other hedge funds have also recently modified their holdings of the business. Krilogy Financial LLC raised its stake in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after purchasing an additional 11 shares in the last quarter. Balentine LLC raised its stake in shares of Merck & Co., Inc. by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after purchasing an additional 20 shares in the last quarter. RB Capital Management LLC raised its stake in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after purchasing an additional 23 shares in the last quarter. Bath Savings Trust Co raised its stake in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after purchasing an additional 28 shares in the last quarter. Finally, Stillwater Investment Management LLC raised its stake in shares of Merck & Co., Inc. by 0.8% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock valued at $296,000 after purchasing an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 73.63% of the company’s stock.

Merck & Co., Inc. (MRK) traded up $1.06 during midday trading on Friday, reaching $58.66. 12,343,067 shares of the company’s stock traded hands, compared to its average volume of 11,430,000. Merck & Co., Inc. has a 1 year low of $53.63 and a 1 year high of $66.80. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. The company has a market cap of $159,990.00, a PE ratio of 56.95, a price-to-earnings-growth ratio of 2.87 and a beta of 0.76.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same quarter in the prior year, the firm earned $1.07 EPS. Merck & Co., Inc.’s quarterly revenue was down 2.0% on a year-over-year basis. equities research analysts anticipate that Merck & Co., Inc. will post 3.95 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, January 8th. Shareholders of record on Friday, December 15th were given a $0.48 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $1.92 annualized dividend and a yield of 3.27%. Merck & Co., Inc.’s dividend payout ratio is 186.41%.

Merck & Co., Inc. declared that its board has initiated a stock repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Leerink Swann upped their target price on shares of Merck & Co., Inc. from $69.00 to $70.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Jefferies Group reiterated a “sell” rating and set a $55.00 price objective on shares of Merck & Co., Inc. in a research note on Friday, October 20th. BMO Capital Markets reiterated an “outperform” rating and set a $72.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, October 12th. Finally, Citigroup upgraded shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and set a $72.00 price objective on the stock in a research note on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $66.06.

In other Merck & Co., Inc. news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.25% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Carnick & Kubik Group LLC Invests $1.38 Million in Merck & Co., Inc. (NYSE:MRK)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/21540-shares-in-merck-co-inc-mrk-acquired-by-carnick-kubik-group-llc.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply